日本版創薬エコシステムの確立に向けて—創薬におけるスタートアップの役割と日本に適したあり方
Saved in:
| Published in | YAKUGAKU ZASSHI Vol. 145; no. 7; pp. 617 - 628 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | Japanese |
| Published |
公益社団法人 日本薬学会
01.07.2025
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Author | 奥山, 亮 |
|---|---|
| Author_xml | – sequence: 1 fullname: 奥山, 亮 organization: 立命館アジア太平洋大学国際経営学部 |
| BookMark | eNo9kEtLAlEUxy9RkJn7vsTUfczLZUgvENrUergzcyc1s3Bs0a57B8rHpiB0ExRCYSgtigij6Lt0UOtbNKl0OJwD5_x_58B_Ac2WDksCoSWClwnV7ZUTvn8c5vLL1NAwxsSYQQnCdEszKCOzKIExI5qZxmwepcIw72JM4zCInUDnw9bd8Lo3qlUHtZfvZg9UB9QzqFdQfYjOILoF-Thqv426DZDdwcUlyDjvv06vpnrZBVn_G6rGH6I-IXqHqAqqDVEEUSvGBx_9Qe0JZGfyK0Z-5APIeHUDUoGqD5v9RTQX8GIoUtOeRLvrazuZTS27vbGVWc1qBWriiiYs1_R927KYrQcEBxZ2TSG466cF8zzm2x6jhm_RIE0FsV3mGp5NfZcSIojOTZMl0ebkbiGs8D3hHJXzB7x84vByJe8VhTN10iG64VjjSg1n7Om_xMvxslPg7BdwqKKr |
| ContentType | Journal Article |
| Copyright | 2025 公益社団法人日本薬学会 |
| Copyright_xml | – notice: 2025 公益社団法人日本薬学会 |
| DOI | 10.1248/yakushi.25-00015 |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1347-5231 |
| EndPage | 628 |
| ExternalDocumentID | article_yakushi_145_7_145_25_00015_article_char_ja |
| GroupedDBID | .55 123 29R 2WC ADBBV ALMA_UNASSIGNED_HOLDINGS BAWUL CS3 DIK E3Z EBS EJD F5P GX1 HH5 JMI JSF JSH MOJWN OVT P2P RJT RNS RZJ X7M XSB |
| ID | FETCH-LOGICAL-j260t-e7b6dd877384f10f70b6eeabd9e3cc3d8c325d72f92e18b3b5c82db211e14a663 |
| ISSN | 0031-6903 |
| IngestDate | Thu Aug 07 14:07:02 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Language | Japanese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-j260t-e7b6dd877384f10f70b6eeabd9e3cc3d8c325d72f92e18b3b5c82db211e14a663 |
| OpenAccessLink | https://www.jstage.jst.go.jp/article/yakushi/145/7/145_25-00015/_article/-char/ja |
| PageCount | 12 |
| ParticipantIDs | jstage_primary_article_yakushi_145_7_145_25_00015_article_char_ja |
| PublicationCentury | 2000 |
| PublicationDate | 2025/07/01 |
| PublicationDateYYYYMMDD | 2025-07-01 |
| PublicationDate_xml | – month: 07 year: 2025 text: 2025/07/01 day: 01 |
| PublicationDecade | 2020 |
| PublicationTitle | YAKUGAKU ZASSHI |
| PublicationTitleAlternate | 薬学雑誌 |
| PublicationYear | 2025 |
| Publisher | 公益社団法人 日本薬学会 |
| Publisher_xml | – name: 公益社団法人 日本薬学会 |
| References | 9) Okuyama R., Pharmaceutics, 15, 1794 (2023). 23) Morimoto K., Seisakuken News from Office of Pharmaceutical Industry Research, 71, 57–65 (2024). 32) Okuyama R., Tsujimoto M., J. Jpn. Soc. Intellect. Prod., 13, 127–134 (2017). 11) Okuyama R., Drug Discov. Today, 29, 103866 (2024). 13) Khanna I., Drug Discov. Today, 17, 1088–1102 (2012). 25) Mano H., “Sekai to Nihon no Souyaku no Genjyo.”: 〈https://www.cas.go.jp/jp/seisaku/souyakuryoku/dai1/siryou5.pdf〉, cited 3 April, 2025. 7) Wouters O. J., McKee M., Luyten J., JAMA, 323, 844–853 (2020). 5) Yamaguchi S., Kaneko M., Narukawa M., Clin. Transl. Sci., 14, 1113–1122 (2021). 24) Kagii H., Research Paper from Office of Pharmaceutical Industry Research, 77, 1–66 (2021). 8) Kneller R., Nat. Rev. Drug Discov., 9, 867–882 (2010). 35) Zucker L. G., Darby M. R., J. Technol. Transf., 26, 37–58 (2001). 3) Freeman C., Camb. J. Econ., 19, 5–24 (1995). 1) Prime Minister’s Office of Japan. “Souyaku Ecosystem Summit.”: 〈https://www.kantei.go.jp/jp/101_kishida/actions/202407/30souyaku.html〉, cited 3 April, 2025. 31) Okuyama R., Osada H., Proceedings of PICMET2013, 2704–2710 (2013). 4) Okuyama R., “Science-based Innovation,” 1st ed., Jichosha, Tokyo, 2020. 19) Schulze U., Ringel M., Nat. Rev. Drug Discov., 12, 419–420 (2013). 20) Zozaya N., Villaseca J., Fernández I., Abdalla F., Cadenas-Noreña B., Calleja M. A., Gómez-Pajuelo P., Mestre-Ferrándiz J., Oliva-Moreno J., Trillo J. L., Hidalgo-Vega A., Appl. Health Econ. Health Policy, 22, 297–313 (2024). 26) Okuyama R., Pathogens, 11, 1469 (2022). 14) IQVIA. “Global Trends in R&D 2022.”: 〈https://www.iqvia.com/insights/the-iqvia-institute/reports/global-trends-in-r-and-d-2022〉, cited 17 December, 2024. 37) Yamamoto T., Ishino M., Miyamoto I., Okuyama R., UNITTJ, 17, 92–96 (2022). 22) Based on a lecture presented at the 38th Annual Meeting of Japan Society for Science Policy and Research Management, Online, on 29 October, 2023. 30) Corporate Direction. “Souyakukei bioventure keiei no youten.”: 〈https://www.meti.go.jp/policy/mono_info_service/mono/bio/Bioventure/bioventurehoukokusyo.pdf〉, cited 17 December, 2024. 38) Kessel M., Vickrey C., Eiki N., Iyakukeizai, 1708, 10–13 (2024). 6) Shareef U., Altaf A., Ahmed M., Akhtar N., Almuhayawi M. S., Al Jaouni S. K., Selim S., Abdelgawad M. A., Nagshabandi M. K., Saudi Pharm. J., 32, 101913 (2024). 12) Chandy R. K., Tellis G. J., J. Mark., 64, 1–17 (2000). 10) Okuyama R., Vaccines (Basel), 11, 1737 (2023). 15) Lombardino J. G., Lowe J. A. 3rd, Nat. Rev. Drug Discov., 3, 853–862 (2004). 28) Global Entrepreneurship Monitor. “Entrepreneurial Behavior and Attitudes.”: 〈https://gemconsortium.org/economy-profiles/japan-2〉, cited 17 December, 2024. 18) Fernald K., Weenen T., Sibley K., Claassen E., Technol. Invest., 4, 168–178 (2013). 34) Zucker L. G., Darby M. R., Armstrong J. S., Manage. Sci., 48, 138–153 (2002). 2) Nishino F., Hanzawa S., Hitotsubashi Bull. Soc. Sci., 12, 1–26 (2020). 36) Okuyama R., J. Risk Financ. Manag., 17, 539 (2024). 17) Moroy G., Martiny V. Y., Vayer P., Villoutreix B. O., Miteva M. A., Drug Discov. Today, 17, 44–55 (2012). 29) Cabinet Office Seidokadai working group. “Sankosiryo 1.”: 〈https://www8.cao.go.jp/cstp/tyousakai/seidokadai/2kai/sanko1.pdf〉, cited 3 April, 2025. 16) Desai M. C., Chackalamannil S., Curr. Opin. Drug Discov. Devel., 13, 376–378 (2010). 33) Zucker L. G., Darby M. R., Brewer M. B., Am. Econ. Rev., 88, 290–306 (1998). 21) Okuyama R., Biol. Pharm. Bull., 46, 718–724 (2023). 27) Sakurai T. Shodai Bus. Rev., 10, 81–100 (2020). |
| References_xml | – reference: 28) Global Entrepreneurship Monitor. “Entrepreneurial Behavior and Attitudes.”: 〈https://gemconsortium.org/economy-profiles/japan-2〉, cited 17 December, 2024. – reference: 8) Kneller R., Nat. Rev. Drug Discov., 9, 867–882 (2010). – reference: 1) Prime Minister’s Office of Japan. “Souyaku Ecosystem Summit.”: 〈https://www.kantei.go.jp/jp/101_kishida/actions/202407/30souyaku.html〉, cited 3 April, 2025. – reference: 6) Shareef U., Altaf A., Ahmed M., Akhtar N., Almuhayawi M. S., Al Jaouni S. K., Selim S., Abdelgawad M. A., Nagshabandi M. K., Saudi Pharm. J., 32, 101913 (2024). – reference: 4) Okuyama R., “Science-based Innovation,” 1st ed., Jichosha, Tokyo, 2020. – reference: 10) Okuyama R., Vaccines (Basel), 11, 1737 (2023). – reference: 12) Chandy R. K., Tellis G. J., J. Mark., 64, 1–17 (2000). – reference: 19) Schulze U., Ringel M., Nat. Rev. Drug Discov., 12, 419–420 (2013). – reference: 30) Corporate Direction. “Souyakukei bioventure keiei no youten.”: 〈https://www.meti.go.jp/policy/mono_info_service/mono/bio/Bioventure/bioventurehoukokusyo.pdf〉, cited 17 December, 2024. – reference: 9) Okuyama R., Pharmaceutics, 15, 1794 (2023). – reference: 15) Lombardino J. G., Lowe J. A. 3rd, Nat. Rev. Drug Discov., 3, 853–862 (2004). – reference: 38) Kessel M., Vickrey C., Eiki N., Iyakukeizai, 1708, 10–13 (2024). – reference: 37) Yamamoto T., Ishino M., Miyamoto I., Okuyama R., UNITTJ, 17, 92–96 (2022). – reference: 31) Okuyama R., Osada H., Proceedings of PICMET2013, 2704–2710 (2013). – reference: 34) Zucker L. G., Darby M. R., Armstrong J. S., Manage. Sci., 48, 138–153 (2002). – reference: 16) Desai M. C., Chackalamannil S., Curr. Opin. Drug Discov. Devel., 13, 376–378 (2010). – reference: 23) Morimoto K., Seisakuken News from Office of Pharmaceutical Industry Research, 71, 57–65 (2024). – reference: 24) Kagii H., Research Paper from Office of Pharmaceutical Industry Research, 77, 1–66 (2021). – reference: 18) Fernald K., Weenen T., Sibley K., Claassen E., Technol. Invest., 4, 168–178 (2013). – reference: 35) Zucker L. G., Darby M. R., J. Technol. Transf., 26, 37–58 (2001). – reference: 3) Freeman C., Camb. J. Econ., 19, 5–24 (1995). – reference: 7) Wouters O. J., McKee M., Luyten J., JAMA, 323, 844–853 (2020). – reference: 14) IQVIA. “Global Trends in R&D 2022.”: 〈https://www.iqvia.com/insights/the-iqvia-institute/reports/global-trends-in-r-and-d-2022〉, cited 17 December, 2024. – reference: 36) Okuyama R., J. Risk Financ. Manag., 17, 539 (2024). – reference: 5) Yamaguchi S., Kaneko M., Narukawa M., Clin. Transl. Sci., 14, 1113–1122 (2021). – reference: 29) Cabinet Office Seidokadai working group. “Sankosiryo 1.”: 〈https://www8.cao.go.jp/cstp/tyousakai/seidokadai/2kai/sanko1.pdf〉, cited 3 April, 2025. – reference: 25) Mano H., “Sekai to Nihon no Souyaku no Genjyo.”: 〈https://www.cas.go.jp/jp/seisaku/souyakuryoku/dai1/siryou5.pdf〉, cited 3 April, 2025. – reference: 2) Nishino F., Hanzawa S., Hitotsubashi Bull. Soc. Sci., 12, 1–26 (2020). – reference: 11) Okuyama R., Drug Discov. Today, 29, 103866 (2024). – reference: 17) Moroy G., Martiny V. Y., Vayer P., Villoutreix B. O., Miteva M. A., Drug Discov. Today, 17, 44–55 (2012). – reference: 21) Okuyama R., Biol. Pharm. Bull., 46, 718–724 (2023). – reference: 33) Zucker L. G., Darby M. R., Brewer M. B., Am. Econ. Rev., 88, 290–306 (1998). – reference: 22) Based on a lecture presented at the 38th Annual Meeting of Japan Society for Science Policy and Research Management, Online, on 29 October, 2023. – reference: 32) Okuyama R., Tsujimoto M., J. Jpn. Soc. Intellect. Prod., 13, 127–134 (2017). – reference: 13) Khanna I., Drug Discov. Today, 17, 1088–1102 (2012). – reference: 20) Zozaya N., Villaseca J., Fernández I., Abdalla F., Cadenas-Noreña B., Calleja M. A., Gómez-Pajuelo P., Mestre-Ferrándiz J., Oliva-Moreno J., Trillo J. L., Hidalgo-Vega A., Appl. Health Econ. Health Policy, 22, 297–313 (2024). – reference: 26) Okuyama R., Pathogens, 11, 1469 (2022). – reference: 27) Sakurai T. Shodai Bus. Rev., 10, 81–100 (2020). |
| SSID | ssib002222518 ssib002484306 ssib001136365 ssib002223935 ssib002484304 ssib002484305 ssib000959844 ssib002822080 ssib003105265 ssib023161479 ssj0023355 ssib000576198 ssib002499502 ssib003105266 ssib000937675 ssib000972830 ssib001536036 ssib002222551 ssib058494605 ssib058494604 |
| Score | 2.4731295 |
| SecondaryResourceType | review_article |
| SourceID | jstage |
| SourceType | Publisher |
| StartPage | 617 |
| SubjectTerms | corporate spin-off drug discovery ecosystem modality policy startup |
| Title | 日本版創薬エコシステムの確立に向けて—創薬におけるスタートアップの役割と日本に適したあり方 |
| URI | https://www.jstage.jst.go.jp/article/yakushi/145/7/145_25-00015/_article/-char/ja |
| Volume | 145 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | YAKUGAKU ZASSHI, 2025/07/01, Vol.145(7), pp.617-628 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrR1NaxQxdKh68SJ-4jd7cHqpqzPJJDM5Ztqt1YIItqBelp2PRSuo2PZQT84sqG0vCtJeBKWgVFo8KCIVxf9iaKs_wLsvmcxstlZQEbLDy_dL3mTfe5mXF8s6ldB2G7WStA6iLTwc6tQZidv11KGR04riqNVWBrIX6ci4d-EKudK344dhtTQ9FZ2J7217ruRfqAppQFd5SvYvKFs1CgkAA33hCRSG5x_R2G5Qm_k2JwoYtPmg3fDtgNlBYDeIBELICmxGVRa2A2TzQAMhLgG_BJgCIFANcEcBrs0bsmUOZbgCQjsIy6xQ9sUcm7k6pQI4LW0pvN_gU1RXQMB7q6OyiwoxAIY1YuFgiWo5HMBNp2ANMN9AntjhkGqnQAOVWcF2c1ghxhTASsTKBtlwiTMqUeWqOoUuTHH_Kh8dPwe_gWv88uWRaoNaYsFVkHi5MsCbbjc8Ob28Ye7EIFJZ7RZrR42AaFKzUPUM6ENVNUpI4VjiAuRlRDcZ8oHthlkRApobUsTy5MQybrIy7NYpcwrukBbcC3u-3Flwe9hb4a5Tr2PfYFa0ODWr5R5aHNL_haUiTx4TmWndnJ68fuOMHLWUs7viQ2XUqZdBUxcFpZI0ffVERNk4kGZZRJ4obE6AWrMLgXandkLOjxpahNxbM7QEtsXlECMsMC9tYL50Y9fVAlxMMTW9EGIKgpohtQITM0QyFTc-jkuRmeEer38eNnctVHxrvtG-xxhxeowVkGOwSdCoei6lKOJVfaAfyMzdj-egIjDPcKGk412XohiT4qIW_UZoawxA6-xWsoGcPQFaZ2mxqoTosb3WHq391nhBoH1W30Rrv9V_qXCfP3O6NtY9DTp5utZfu9R1rD9zwHq4sfhy49nq5uyj9dn33xZWRb4s8nci_yDyNdF5IDovRPZmc-nj5sq8yFbWHz8RGYRXX-8_1eWzFZHNycR8XlbJv4jOJ9F5JPIl0emIziJUX_-8tj77VmTLRV9Q5Xv2WmSQ9VxkucjnNhbWDlrjw42xwZG6vkimPoGoM1VP_YgmSeD7OPDartP2nYimaStKWIrjGCdBjBFJfNRmKHWDCEckDlASIddNXa8FOtkha-et27fSw1YtgtzYIYmD28hLccpQ7NEkwsAJSSv2_SMWLya4eafwFtT8-2Vx9D-0ccza3f2LOm7tnLo7nZ4A9WkqOqkW20_r_jnl |
| linkProvider | Flying Publisher |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E6%97%A5%E6%9C%AC%E7%89%88%E5%89%B5%E8%96%AC%E3%82%A8%E3%82%B3%E3%82%B7%E3%82%B9%E3%83%86%E3%83%A0%E3%81%AE%E7%A2%BA%E7%AB%8B%E3%81%AB%E5%90%91%E3%81%91%E3%81%A6%E2%80%94%E5%89%B5%E8%96%AC%E3%81%AB%E3%81%8A%E3%81%91%E3%82%8B%E3%82%B9%E3%82%BF%E3%83%BC%E3%83%88%E3%82%A2%E3%83%83%E3%83%97%E3%81%AE%E5%BD%B9%E5%89%B2%E3%81%A8%E6%97%A5%E6%9C%AC%E3%81%AB%E9%81%A9%E3%81%97%E3%81%9F%E3%81%82%E3%82%8A%E6%96%B9&rft.jtitle=YAKUGAKU+ZASSHI&rft.au=%E5%A5%A5%E5%B1%B1%2C+%E4%BA%AE&rft.date=2025-07-01&rft.pub=%E5%85%AC%E7%9B%8A%E7%A4%BE%E5%9B%A3%E6%B3%95%E4%BA%BA+%E6%97%A5%E6%9C%AC%E8%96%AC%E5%AD%A6%E4%BC%9A&rft.issn=0031-6903&rft.eissn=1347-5231&rft.volume=145&rft.issue=7&rft.spage=617&rft.epage=628&rft_id=info:doi/10.1248%2Fyakushi.25-00015&rft.externalDocID=article_yakushi_145_7_145_25_00015_article_char_ja |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0031-6903&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0031-6903&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0031-6903&client=summon |